Achieve Life Sciences (ACHV) Total Non-Current Liabilities (2010 - 2026)

Achieve Life Sciences has disclosed Total Non-Current Liabilities across 12 years of filings, most recently posting $21.2 million for Q1 2026.

• Quarterly Total Non-Current Liabilities rose 33.56% year-over-year to $21.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.2 million (up 33.56% YoY) and the FY2025 annual result came in at $18.7 million, up 12.84% from the prior year.
• Total Non-Current Liabilities rose to $21.2 million in Q1 2026, from $18.7 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $21.9 million in Q2 2024 and troughed at $4.2 million in Q4 2023.
• A 4-year average of $17.0 million and a median of $17.8 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities surged 298.01% — and 2025, when it decreased 21.04%.
• Tracing ACHV's Total Non-Current Liabilities over 4 years: stood at $4.2 million in 2023, then jumped by 298.01% to $16.6 million in 2024, then gained by 12.84% to $18.7 million in 2025, then rose by 13.04% to $21.2 million in 2026.
• Business Quant data shows ACHV's Total Non-Current Liabilities at $21.2 million in Q1 2026, $18.7 million in Q4 2025, and $18.4 million in Q3 2025.